Orexo signs up Invida for Abstral in Asia Pacific
This article was originally published in Scrip
Executive Summary
Orexo, the Swedish specialty pharma company focusing on pain management and inflammation, has granted Invida Group an exclusive licence covering the Asia Pacific region for Abstral (fentanyl citrate) breakthrough cancer pain treatment. The deal almost completes global coverage for the product. Indeed, the Swedish company is now looking for a partner to take up rights to the drug for the Latin American markets.